Gestational Diabetes Mallitus (GDM) Management Summary

Gestational Diabetes Mellitus

A Simple, Illustrated Management Plan

1. Diagnosis

Diagnosed by an oral glucose tolerance test (OGTT), typically performed at 24–28 weeks of gestation (earlier if there is a prior history of GDM or other risk factors).

Diagnostic thresholds vary by protocol used locally (e.g. WHO 75-g 2-hour test vs ADA/Carpenter–Coustan 100-g 3-hour test). Follow whichever criteria are used in your unit, since the source manual predates the now widely adopted IADPSG one-step criteria.

Once diagnosed, refer promptly to a joint diabetes–obstetric antenatal clinic.

2. Initial Assessment

• Confirm gestational age accurately.
• Baseline weight/BMI, blood pressure, urinalysis.
• Assess risk factors: obesity, previous GDM, previous macrosomic baby, family history of diabetes, ethnicity.
• Educate about self-monitoring of blood glucose (SMBG), diet, and exercise.
• Involve a multidisciplinary team: obstetrician, diabetes physician, diabetes specialist nurse/midwife, and dietitian.

3. First-Line Treatment: Diet and Exercise

Diet and lifestyle change are first-line therapy for essentially all women with GDM.

Dietary principles

• Favor low glycemic index (GI) carbohydrates rather than strict restriction
• Avoid severe caloric restriction (<1200 kcal/day) — risks ketonemia
• Overweight/obese women: moderate restriction (~25 kcal/kg/day)
• Refer to a dietitian for individualized, culturally appropriate advice

Exercise

• Regular moderate activity, e.g. walking 20 min once or twice daily
• Best done after meals to blunt postprandial glucose rise
• Combined with diet, reduces need for medication

About 85% of women with GDM achieve adequate control with diet and exercise alone; roughly 15% need additional pharmacological therapy.

4. Glucose Monitoring and Targets

Home capillary blood glucose monitoring (fasting and post-meal) is standard once GDM is diagnosed.

Timing	Target
Fasting	3.5–5.9 mmol/L (63–106 mg/dL)
1-hour postprandial	< 7.8 mmol/L (140 mg/dL)
2-hour postprandial	< 6.7 mmol/L (120 mg/dL)

Evidence suggests postprandial monitoring/targets give better perinatal outcomes (lower birthweight, fewer large-for-gestational-age infants) than preprandial monitoring alone, though at the cost of somewhat higher insulin requirements when insulin is used.

Serial ultrasound assessment of fetal growth (e.g. abdominal circumference) can help guide the threshold for starting pharmacological treatment, particularly if macrosomia is suspected.

5. Escalation to Pharmacological Therapy

If glycemic targets are not met with diet and exercise alone, options include:

Insulin

• Regarded as the traditional standard of care
• Regimen (basal, prandial, or combination) individualized to the hyperglycemia pattern
• Requirements typically increase as pregnancy advances due to rising insulin resistance

Metformin

• Effective alternative to insulin; no hypoglycemia or weight gain
• Crosses the placenta freely but has not been shown to be teratogenic
• MiG trial: outcomes broadly comparable to insulin, but ~46% needed supplemental insulin; preterm birth slightly more common
• Favorable choice for overweight/obese women given weight profile and ease of use

Glyburide (Glibenclamide)

• Short-acting sulfonylurea; minimal placental transfer
• Effective in most women, but 16–21% eventually need insulin ("glyburide failure")
• Failure predictors: higher glucose challenge result, diagnosis before 25 weeks, older maternal age, multiparity, higher pretreatment fasting glucose
• Not universally available/licensed for this indication — check local practice

Choice between insulin, metformin, and glyburide should follow local guidelines, patient preference, and contraindications (e.g. metformin avoided in renal impairment).

6. Fetal Surveillance

• Serial growth ultrasound to monitor for macrosomia or growth restriction
• Increased surveillance if glycemic control is poor, macrosomia is suspected, or other risk factors are present
• Standard antenatal fetal well-being assessments otherwise apply

7. Timing and Mode of Delivery

• Diet-controlled GDM, no other complications: manage like the general obstetric population (no routine early delivery).
• Insulin-requiring GDM (or suspected macrosomia): consider elective delivery at 38–39 weeks — reduces shoulder dystocia risk without raising cesarean rates.

Individualize based on: glycemic control, estimated fetal weight/macrosomia, fetal growth restriction, maternal preference and obstetric history.

Mode of delivery: vaginal delivery is preferred where appropriate. Cesarean rates are generally higher in GDM pregnancies, partly related to maternal obesity and practice patterns rather than GDM itself.

8. Intrapartum Glycemic Management

Goal: avoid maternal hyperglycemia to reduce risk of fetal acidemia and neonatal hypoglycemia.

GDM Type	Monitoring	Target
Diet-controlled	Every 1–2 hours in established labor	< 7 mmol/L (126 mg/dL); start insulin/dextrose infusion if not met
Insulin-requiring	Hourly, IV dextrose/insulin infusion	4–7 mmol/L (72–126 mg/dL)

9. Postpartum and Neonatal Care

• Encourage early skin-to-skin contact and breastfeeding within the first hour
• Monitor neonate for hypoglycemia, especially if maternal control was suboptimal or medications were used
• Most infants do not require routine NICU admission unless there are specific concerns
• Insulin/medications for GDM are usually stopped immediately after delivery as insulin resistance resolves rapidly

10. Postpartum Follow-up (Maternal)

• Offer a 75-g OGTT at ~6 weeks postpartum to reclassify glucose tolerance
• Advise on weight management, healthy diet, and continued physical activity — reduces future risk of Type 2 diabetes
• Annual screening for diabetes with the primary care physician
• Contraception planning and repeat glucose testing before any future pregnancy (recurrence of GDM is common)
• Breastfeeding should be encouraged; no contraindications related to GDM itself

Summary Flow

This is a simplified educational summary from Swaraj Hospital and Research Institute, Bolangir and is not a substitute for local clinical guidelines or individualized clinical judgment.

Grief Counseling Module: Obstetrics ( GIST)

 

1. Introduction

• Importance of bereavement care in obstetrics.
• Impact of perinatal loss on parents, families, and healthcare staff.

2. Principles of Perinatal Loss Care

• Parent-centred approach: Needs-based, not loss-type-based.
• Multidisciplinary team roles (Midwives, doctors, social workers, spiritual advisors).
• Continuity of care and carer.

3. Empathetic Communication Strategies

• Breaking bad news: Honesty, clarity, and sensitivity.
• Language usage: Using parents' preferred terminology (e.g., "baby" vs "fetus").
• Validating the baby’s existence and acknowledging parenthood.
• Active listening and managing stress/grief in information absorption.

4. Supporting Parents & Families

• Memory making: Options for mementos (photos, footprints).
• Parent-centred decision-making: Birth plans, palliative care, and post-birth care.
• Cultural and religious considerations.
• Support after termination of pregnancy for medical reasons (addressing stigma, guilt, and shame).

5. Clinical Guidelines

• Documentation: Care plans and shared records.
• Aftercare: Referral pathways to community support and follow-up.
• Self-care for staff: Managing secondary traumatic stress.

6. Conclusion & Resources

• Key takeaways.
• Contact list for support services.

RAT BITE — CLINICIAN HANDOUT

                                                   

Patient: __________ DOB/Age: __________ MRN: __________ Date/Time: __________
Bite: ☐ Rat ☐ Other rodent: __________ Provoked? ☐ Yes ☐ No Domestic/pet vs wild: __________
Time since bite: __________ h/d Location: ☐ Hand ☐ Wrist/forearm ☐ Face ☐ Foot ☐ Other: __________
Comorbids (higher risk): ☐ Diabetes ☐ Immunosuppression ☐ Asplenia ☐ Cirrhosis ☐ Vascular insufficiency ☐ Other: __________
Allergies: __________ (reaction: __________)

1) Immediate assessment

• Vitals: T ___ HR ___ RR ___ BP ___ SpO₂ ___ Temp ___
• Red flags requiring urgent escalation/consult/admit:
  ☐ Uncontrolled bleeding ☐ Rapidly progressive swelling/pain ☐ Systemic toxicity ☐ Suspected deep-space hand infection
  ☐ Neurovascular compromise ☐ Suspected tendon/joint/bone involvement ☐ Necrosis/crepitus

2) Wound exam (document)

• Type: ☐ Puncture ☐ Laceration ☐ Crush ☐ Avulsion
• Depth/structures: ☐ Superficial ☐ Deep to fascia ☐ Tendon concern ☐ Joint capsule concern ☐ Bone exposed/seen
• Contamination/foreign body: ☐ None ☐ Dirt/debris ☐ Tooth/foreign body suspected
• Neurovascular/tendon function distal to wound: ☐ Intact ☐ Abnormal (details): __________

3) Wound care (do now)

• ☐ Copious irrigation (NS; high volume)
• ☐ Remove visible debris/foreign material; debride devitalized tissue as needed
• ☐ Analgesia (local/regional/systemic)
• ☐ Consider splint/elevation if hand/wrist involvement
• Primary closure? ☐ No (preferred for puncture/crush/hand/delayed/contaminated) ☐ Yes (criteria met; cosmetically/functional)
  If closed: method __________; follow-up arranged ☐ 24–48 h

4) Imaging / procedures / consult

• X-ray ☐ Yes ☐ No
  Indication: ☐ Foreign body ☐ Fracture ☐ Near joint ☐ Crush injury ☐ Other: __________
• Consult ☐ Hand/ortho ☐ Plastics ☐ ID ☐ Other: __________
  Reason: __________

5) Antibiotics (bite-wound prophylaxis vs treatment)

Use antibiotics for established infection (erythema, warmth, swelling, purulence, lymphangitis, fever) and consider prophylaxis for higher-risk wounds (e.g., hand, deep puncture/crush, devitalized tissue/contamination, suspected joint/bone/tendon involvement, poor circulation, immunocompromise). ⁽²⁾

• No skin break: ☐ No antibiotics
• Broken skin: prophylaxis indicated? ☐ Yes ☐ No
  Rationale (check): ☐ Hand/face/genitals ☐ Deep puncture/crush ☐ Delayed presentation ☐ Comorbidity risk ☐ Other: ______
• Signs of infection present? ☐ Yes ☐ No
• Regimen chosen:
  ☐ Amoxicillin–clavulanate __________ dose __________ route __________ duration __________
  ☐ Penicillin allergy alternative per local guideline: __________________ duration __________
  Notes: If a penicillin allergy is present and doxycycline-based regimens are being used, add anaerobic coverage as per local protocol where appropriate. ⁽³⁾

6) Rat-bite fever (RBF) screen (don’t miss)

RBF can present after rodent exposure with fever, rash, and arthralgia and may rarely lead to invasive disease (e.g., endocarditis); consider if systemic symptoms occur days–weeks after exposure.

• Symptoms now or since bite: ☐ Fever ☐ Rigors ☐ Rash (palms/soles/extremities) ☐ Migratory arthralgia/arthritis ☐ Vomiting/HA
• If suspected RBF:
  ☐ Blood cultures before antibiotics (if feasible)
  ☐ Evaluate for complications as indicated (cardiac exam ± echo if endocarditis concern)
  ☐ Treat as systemic infection per local/ID guidance (often IV beta-lactam or ceftriaxone; doxycycline is a common alternative in beta-lactam allergy)

7) Tetanus prophylaxis (always document)

• Wound category: ☐ Clean/minor ☐ Dirty/major (puncture, devitalized tissue, contaminated)
• Tetanus vaccine status:
  Last Td/Tdap: __________ Primary series complete? ☐ Yes ☐ No/Unknown
• Action:
  ☐ No vaccine needed
  ☐ Td/Tdap booster given today
  ☐ Tetanus immune globulin (TIG) given (if indicated)
  (Antibiotics are not used to prevent tetanus.) ⁽⁴⁾

8) Rabies risk documentation (usually low for rats)

• Animal available for assessment? ☐ Yes ☐ No
• Unusual circumstance (neurologic behavior / local outbreak / public health advice)? ☐ Yes ☐ No
• Plan: ☐ No rabies PEP indicated ☐ Public health consulted: __________ ☐ PEP started
  (If PEP is indicated: start with wound cleansing; HRIG + vaccine schedule per guidance.) ⁽¹⁾

9) Disposition & follow-up

• Disposition: ☐ Home ☐ Observation ☐ Admit (service: __________)
• Follow-up arranged: ☐ 24–48 h (hand/deep/closed/high risk) ☐ 3–5 d ☐ Other: __________
• Return precautions documented (clinician): worsening pain/swelling/erythema, purulence, fever, lymphangitis, reduced ROM, numbness/weakness, or systemic symptoms within 1–3 weeks (RBF concern).

If you tell me your local formulary preferences (or country/health system) and whether you want adult-only vs adult+peds, I can “lock” the antibiotic lines into exact doses/durations for your setting and keep it to a strict single page.

CITED SOURCES

1. Rabies Post-exposure Prophylaxis Guidance | Rabies | CDC. www.cdc.gov
2. Management of bites, human and animal - South & West.  southwest.devonformularyguidance.nhs.uk
3. Human and animal bites | Right Decisions.
   www.rightdecisions.scot.nhs.uk

   
   

Frequently Asked Questions: Molar Pregnancy (Hydatidiform Mole)

 

 

1. What is a molar pregnancy?

A molar pregnancy, or hydatidiform mole, is a rare complication of pregnancy where an abnormal fertilized egg develops into a mass of cysts instead of a healthy fetus. It is a type of gestational trophoblastic disease (GTD).

2. What causes a molar pregnancy?

It is caused by a genetic error during the fertilization process.

•         Complete mole: Occurs when one sperm fertilizes an "empty" egg (lacking maternal DNA). The genetic material is entirely paternal.

•         Partial mole: Occurs when two sperm fertilize one normal egg, resulting in too much genetic material (69 chromosomes instead of the usual 46).

3. What are the common symptoms?

Patients often present with symptoms similar to a normal pregnancy, but more intense:

•         Vaginal bleeding in the first trimester.

•         Severe nausea and vomiting (hyperemesis gravidarum).

•         Rapid uterine growth (uterus larger than expected for gestational age).

•         Passing grape-like cysts from the vagina.

•         High blood pressure, pre-eclampsia symptoms, or hyperthyroidism symptoms.

4. How is it diagnosed?

•         Ultrasound: Typically shows a "snowstorm" appearance or a cluster of grapes.

•         β-hCG levels: Blood tests show unusually high human chorionic gonadotropin (hCG) levels compared to a normal pregnancy of the same stage.

5. What is the treatment?

The standard treatment is an evacuation procedure, usually a Suction Dilatation and Curettage (D&C), to remove the abnormal tissue from the uterus. In some cases, if the patient has completed childbearing and the risk of complications is high, a hysterectomy might be discussed.

6. Why is follow-up so important?

Because there is a risk that some abnormal trophoblastic tissue remains or develops into a more serious, malignant form of GTD (such as choriocarcinoma), regular monitoring of β-hCG levels is mandatory. The goal is to ensure the level drops to zero and stays there.

7. What does the follow-up surveillance involve?

•         Weekly β-hCG: Until the level is undetectable for three consecutive weeks.

•         Monthly β-hCG: For six months following the first undetectable reading to ensure the mole does not recur.

8. Can I get pregnant again?

Yes, most women who have had a molar pregnancy go on to have healthy, normal pregnancies in the future. However, it is strongly advised to use effective contraception during the entire surveillance period. Becoming pregnant during this time would elevate hCG levels, making it impossible to tell if the mole has returned or is malignant.

9. Is a molar pregnancy a type of cancer?

Most molar pregnancies are benign and resolve completely after evacuation. However, in a small percentage of cases, the tissue can become invasive or malignant (Gestational Trophoblastic Neoplasia). This is why the follow-up monitoring is so critical—to detect and treat these cases early, usually with medication (chemotherapy).

10. Will I need chemotherapy?

Only if the β-hCG levels do not return to normal or if there is evidence of malignant trophoblastic disease. If needed, chemotherapy for GTD is highly effective and generally has a very high cure rate.

11. What are the psychological impacts of a molar pregnancy?

It is very common to experience a wide range of emotions, including shock, grief, sadness, and anxiety, even if the pregnancy was early. It is important to remember that a molar pregnancy is a medical event outside of your control. Reaching out for professional counseling, joining a support group, or speaking with your doctor about your feelings can be incredibly helpful during the recovery process.

12. Are there any increased risks for me in future pregnancies?

Generally, no. After a successful recovery and the surveillance period, you are not at a significantly higher risk of having another molar pregnancy. The risk of recurrence is very low (about 1–2%). Your healthcare provider will likely recommend early ultrasound in future pregnancies to confirm viability.

13. What is "Persistent Trophoblastic Disease" (PTD)?

PTD occurs when β-hCG levels do not decline as expected or begin to rise again during the surveillance period. This indicates that some abnormal tissue remains and continues to produce hCG. It is not necessarily "cancer" in the traditional sense, but it does require medical intervention, typically with specialized chemotherapy, to ensure the disease is fully cured.

14. Should I be concerned if my β-hCG levels plateau?

Yes. If β-hCG levels stop declining (plateau) or increase during the monitoring phase, your doctor will need to investigate. This is a common trigger for further imaging (like a chest X-ray or CT scan) to check for residual disease and will prompt a discussion about starting treatment to prevent further complications.

15. Are there different types of chemotherapy used for GTD?

Yes. The chemotherapy used for gestational trophoblastic disease (GTD) is often much more targeted and has different protocols than traditional cancer chemotherapy. Many patients only require a single drug, and the cure rate for this disease is remarkably high, often reaching near 100% with timely treatment.